A new genetic engineering study has found that oral small-molecule GLP-1 drugs activate deep brain pathways linked to desire and reduced cravings in mice. The findings, published by Genetic Engineering News, suggest these therapies directly influence neural circuits involved in food-seeking behavior.
The research demonstrates that the drugs impact brain activity beyond traditional appetite centers, including regions associated with reward and motivation. Researchers observed diminished cravings in the animals, pointing to a mechanism that may help explain the profound weight loss seen in human trials.